



TRANSITION TO CONTINUOUS TRADING

Paris, France and Cambridge, UK – 15th December 2014 – Novacyt (ISIN Code: FR0010397232 - Mnemonic code: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces that its stock will transition to continuous trading starting 15th of December 2014.

This announcement follows Euronext's decision who approved on 11th December 2014 the change of trading category for Novacyt shares on Alternext Paris.

Starting 15th of December 2014 at 9am, the quotation of Novacyt shares will be transferred from fixed trading category to continuous trading from 9am to 5.30pm.

This change in the quotation method will strengthen liquidity for shareholders.

This change happens while the company signed a liquidity contract with Louis Capital Market.

Graham Mullis, Group CEO of Novacyt, commented:

« Following our recent capital increase the continuous trading of Novacyt shares is one of the decisions taken by the Company to ensure better management of the stock and especially enhance liquidity. It will strengthen the share's appeal and will enable to attract new types of investors. »

- Ends -

About Novacyt Group

The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NovaPrep® and a strong international network Novacyt is able to provide an extensive range of oncology and infectious disease products. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts:

International media and investor enquiries:

International Investor & Media

Tony Stephenson

Exitus Communications

+44 (0)7899 796655

tony@exituscommunications.co.uk

French Investor & Media

Sophie Boulila / Emmanuel Huynh,

NewCap

+33 (0)1 44 71 94 91

novacyt@newcap.fr



NOVACYT

Graham Mullis

Chief Executive Officer

+44 7901 514121

Graham.mullis@novacyt.com